Podcasts about travere therapeutics

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for May 5- 11, 2025: FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis The FDA will review Travere Therapeutics' application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision. FDA Accepts BioCryst's NDA for Berotralstat Oral Granules in Children With HAE The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12. SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity Tirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity. Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis Crinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics. Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk Adults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.

Synopsis: In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mission-driven leadership. He dives into Zevra's recent therapeutic milestones, regulatory strategies, and the importance of reflection in high-stakes environments. This conversation offers powerful takeaways for anyone navigating biotech leadership, board management, or rare disease innovation. Biography: Neil F. McFarlane took the reins as President and CEO of Zevra Therapeutics, a commercial-stage rare disease therapeutics company, in October 2023, bringing with him a wealth of experience in the biopharma industry and specific expertise in neurological and rare diseases. Before joining Zevra, he served on the board of Collegium Pharmaceutical Inc. from 2022 to 2024 and was the CEO of Adamas Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neurological diseases, from 2019 until its acquisition by Supernus Pharmaceuticals in 2021. Prior to Adamas, Mr. McFarlane was Chief Operating Officer at Retrophin, Inc. (now Travere Therapeutics, Inc.), from 2016 to 2019, where he managed day-to-day operations. He also held roles of increasing responsibility at UCB, Inc., Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation, which was acquired by Genzyme.

This activity was supported by an educational grant from Travere Therapeutics. Please go to ⁠https://academiccme.com/CKDCE3/⁠ and complete the evaluation to receive your CE/CME Credit. Credit is available through November 21, 2025.

In this week's episode, Rachel Couchenour, Vice President Global Medical Affairs at Travere Therapeutics, discusses the importance of building your internal and external network. Learn more about…

Jon Denny has been a National Executive Sales and Marketing Recruiter for over 24 years in the Pharmaceutical, Biotech, Medical Devices, and Medical Diagnostics Industries with leading national recruitment firm, Buckman Enochs Coss & Associates (BEC Search). Established in 1979, BEC Search specializes in helping the best Healthcare and Life Science companies find the best people for every level of their organization, Commercial, Med Affairs, Sales, and Marketing Executives - for Projects and Retained. They have partnered with leading companies such as Allergan/Abbvie, Biodesix, Amgen, Apellis, Cardinal Health, Dompe, Genentech, Lantheus, Shionogi, Inc., Supernus Pharmaceuticals, Takeda, Travere Therapeutics, Vertos Medical, and many others.  Before joining BEC, Jon spent over two years in Accounting and Finance Recruitment for a leading staffing firm and 4 years in College/University Recruitment.  In the last two decades, Jon has helped countless individuals in healthcare sales, marketing, and clinical roles find employment opportunities that have been life-changing and he has several current clients he helped early on in their careers. Jon attributes his transformative approach to a unique blend of business acumen, strong work ethic, empathy, and ability to connect with individuals. These traits find their roots in his competitive collegiate athletic background, where he played football for four years at his alma mater, Ohio Northern University. What you'll learn in this episode: The importance of human connection in leadership and recruiting The crucial role of preparation in the recruiting process, for both the candidate and recruiter Reasons why people leave their jobs and how they often relate to issues with management or a lack of development opportunities The impact of a transformational approach in recruitment for greater success How understanding a candidate's story and motivation reveals insights into their suitability The necessity of understanding a candidate's purpose and its connection to career aspirations The high value placed on intangible qualities such as character, integrity, and work ethic in potential hires Additional Resources:  Jon's LinkedIn Jon's Twitter/X  About BEC Search's Website: www.becsearch.com LinkedIn Facebook Instagram Twitter/X Listen to Episode 86 with Jon Denny

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. According to recent data from KFF, over 10 million people have lost their Medicaid coverage as states continue to assess eligibility and terminate coverage for those deemed ineligible. This comes as states have assessed the eligibility of 28 million Americans in total. The decline in employment in skilled nursing facilities is raising concerns, with regulators, healthcare industry leaders, and workers' unions split on how to make roles more attractive. Leapfrog Group CEO Leah Binder noted that while hospitals have improved on infection control following the COVID-19 spike, patient experience scores have declined, potentially due to ongoing labor shortages. In healthcare worker news, nearly 1,400 nurses at Providence Regional Medical Center in Everett, Washington are set to begin a five-day strike on November 14. Concerns about the demand for obesity drugs impacting medical devices and procedures have led to a $370 billion decrease in value across the medtech sector, according to research. In regulatory news, CMS has finalized rules for Medicare hospital and doctor payments for 2024, as well as implementing fixes for the 340B drug pricing program and price transparency requirements. Finally, disputes between hospitals and workers are expected to continue even as the pandemic subsides, potentially leaving patients caught in the middle amid strikes and bottlenecks in care.Bristol Myers Squibb (BMS) has acquired an antibody-drug conjugate (ADC) asset from South Korean biotech Orum Therapeutics for $100 million upfront. This deal comes after BMS's previous acquisition of Tubulis in April 2023, as the company continues its buying spree in the ADC space. BMS is expanding its portfolio of ADCs, which are a type of targeted cancer therapy that combines an antibody with a chemotherapy drug. The acquisition from Orum Therapeutics will add to BMS's pipeline of innovative cancer treatments. In other news, Kodiak Sciences is giving its failed eye drug, tarcocimab tedromer, another chance after new data convinced the company to continue its development. The drug had previously experienced late-stage failures, but the positive results from a phase III trial have prompted Kodiak Sciences to revive the project. Pfizer is implementing a $3.5 billion cost-cutting program, which includes laying off approximately 200 employees at its manufacturing facility in Kalamazoo, Michigan. The company is facing declining sales from its COVID-19 business and aims to mitigate the impact through cost reductions. Travere Therapeutics is hoping to regain momentum for its kidney disease drug, filspari, after two late-stage failures. The company has released positive results from two phase III studies in an attempt to revive the drug's prospects in treating iga nephropathy and focal segmental glomerulosclerosis. Overall, these developments highlight ongoing activity and advancements in the biopharmaceutical industry. Companies like BMS, Kodiak Sciences, Pfizer, and Travere Therapeutics are actively pursuing new opportunities and strategies to drive innovation and address unmet medical needs.Pharmaceutical companies like J&J and Pfizer have established in-house bioethics expertise to address the numerous ethical issues facing the industry. One example is direct-to-consumer advertising, which bioethics professor Arthur Caplan describes as a "disaster." Caplan argues that these ads, which often have large budgets, are minimally effective and unlikely to influence patients to ask their doctors about specific medications. Caplan believes that addressing these ethical considerations could help improve the pharmaceutical industry's reputation. Additionally, investor concerns about the impact of obesity drugs on medical devices and procedures have led to a $370 billion decrease in the value of medtech stocks. Thermo Fisher Scientific has r

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerHiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.Co-Chair/PlannerProf. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Brother Fred Betzold was born in Emmett, Idaho and grew up working on his family's apple farm. Brother Betzold joined the church at the age of 18 after several years of fellowship from his childhood friends. A year after joining the church he again followed the example of his friends and was called to serve a two year church mission in San Bernardino, California. Following his mission, he attended the University of Utah, graduating in 1995. While attending college he married his beautiful wife Amy.  Brother Betzold has lived in Middleton, Idaho for the past 20 years. He has served in many capacities, including Bishop and Stake President. He works for Travere Therapeutics as an immunology specialist. When Brother Betzold has free time he enjoys being in the great outdoors of Idaho with his family and friends. Fred and Amy are the parents of three children, and two grandchildren.

Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental complications of kidney disease, which is kidney failure, where you essentially wind up on dialysis. This is a treatment option where patients need to go into a clinic and be hooked up to a machine which cleans their blood three times a week. Or the other option is transplantation. One of the things that we have worked on is a molecule called sparsentan to try and avoid kidney failure." "Sparsentan is an investigational product candidate. It is a single molecule that doesn't suppress the immune system, which I think for a lot of our patients that's very important. It blocks two hormones that are in the path of causing damage within the kidney. What we have found with sparsentan is it reduces the pressure within the kidney, and it causes some remodeling within the kidney that reduces leakage of protein. When you leak protein within your kidney, that causes the kidney to then not clear toxins and then ultimately to progress faster causing kidney failure." @TravereRare #TravereTherapeutics #RareDiseases #RareKidneyDisease #KidneyDisease #EarlyDiagnosis Travere.com Listen to the podcast here

Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental complications of kidney disease, which is kidney failure, where you essentially wind up on dialysis. This is a treatment option where patients need to go into a clinic and be hooked up to a machine which cleans their blood three times a week. Or the other option is transplantation. One of the things that we have worked on is a molecule called sparsentan to try and avoid kidney failure." "Sparsentan is an investigational product candidate. It is a single molecule that doesn't suppress the immune system, which I think for a lot of our patients that's very important. It blocks two hormones that are in the path of causing damage within the kidney. What we have found with sparsentan is it reduces the pressure within the kidney, and it causes some remodeling within the kidney that reduces leakage of protein. When you leak protein within your kidney, that causes the kidney to then not clear toxins and then ultimately to progress faster causing kidney failure." @TravereRare #TravereTherapeutics #RareDiseases #RareKidneyDisease #KidneyDisease Travere.com Download the transcript here

Description: In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Dr Richard Glassock, member of the work group, to hear his insights on the key takeaways from the guideline, and what has changed in this iteration. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. Reference: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. Disclosures: Dr Richard Glassock declares the following: Stock Ownership - Reata Pharmaceuticals Speakers Bureau - Aurinia Advisory Board - Alexion, Bio-Cryst, Novartis, Otsuka, RenaSight, Travere, Vertex Consultant - Alexion, Arrowhead, Aurinia, Bio-Cryst, Calliditas, Chinook, Equillium, Horizon Pharma, Ionis, Midornid, Nephro-Sys, Omeros, River3Renal, Therini Bio, Travere, Vera Pharmaceuticals Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of FSGS. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

In 2021, a work group of international experts published an update to the 2012 iteration of this guideline. To do so they reviewed the latest evidence through a systematic literature review, with the aim of providing a useful resource for clinicians caring for individuals with glomerular disease through actionable recommendations. In this episode we speak to Professor Jürgen Floege, co-chair of the work group, to hear his insights on the key takeaways, and the clinical data that has emerged since the guideline update was made. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.  References available here Disclosures: Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.  This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.  Discussion of Off-Label, Investigational or Experimental Drug Use: Corticosteroids are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

Current standard of care for IgA nephropathy (IgAN) involves optimized supportive care, antihypertensives, and dietary and lifestyle modifications. Despite these interventions, ~30% of patients progress to end stage renal disease. Recent approvals of delayed-release budesonide for IgAN and dapagliflozin for chronic kidney disease, and further investigational agents have the potential to alter the treatment landscape for IgAN. In this episode, Professor Rosanna Coppo offers her expert insight into the potential clinical implications of current and investigational therapies, both now and in the future. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: References available here This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education. Disclosures: Prof. Rosanna Coppo has no disclosures to declare. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. The content for this series was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. Discussion of Off-Label, Investigational or Experimental Drug Use: Atrasentan, C5 inhibitor RNA therapies, eculizumab, empagliflozin, iptacopan, narsoplimab, ravulizumab, and sparsentan are mentioned in the context of the treatment of IgA nephropathy and reducing kidney function decline or failure. Sparsentan is also discussed in the context of the treatment of focal segmental glomerulosclerosis. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

While FSGS was once thought to be a single disease entity, it is now understood to be a pattern of injury caused by diverse mechanisms, but classifying FSGS accurately can be challenging. In this episode, we provide an overview of these classifications and risk factors that can help stratify disease progression risk and assist with determining management approaches. To help understand how we can most effectively and accurately classify FSGS, we are joined by Professor An De Vriese, who is head of the Division of Nephrology and Infectious Disease at the AZ Sint-Jan hospital in Bruges, Belgium. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. De Vriese AS et al. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach. J Am Soc Nephrol 2018;29(3):759-774. 2. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1–S276. 3. Jacobs-Cachá C et al. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers. Clin Kidney J 2020;14(2):482-491. 4. Friedman DJ & Pollak MR. APOL1 nephropathy: From genetics to clinical applications. CJASN, 2021;16(2):294-303. 5. Zee J et al. APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology. 2021;36(9):2747-2757. 6. Shabaka A et al. Focal segmental glomerulosclerosis: State-of-the-art and clinical perspective. Nephron 2020;144(9):413-427. Disclosures: Prof. An De Vriese has no disclosures to announce. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

IgA nephropathy presents with a clinically diverse set of symptoms of wide-ranging severity and a varied disease course. As our understanding of IgA nephropathy has improved, various tools have been developed to help assess risk of progression to kidney failure. This episode offers insight into the use of freely available tools that can assist with the management of IgA nephropathy. We are joined by Dr Andrew Bomback to discuss how these tools are applied in the clinic. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. Penfold RS, et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137-148. 2. Rodrigues JC, et al. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686. 3. Trimarchi H et al. Oxford classification of IgA nephropathy 2016: An update from IgA nephropathy classification working groups. Kidney Int 2017;91(5):1014–1021. 4. Barbour S et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019;179(7):942-952. 5. International IgAN Prediction Tool at Biopsy. Available at: https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool. Accessed May 2022. 6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. 7. Thompson A et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019;14:469–481. Disclosures: Dr Andrew Bomback declares the following: Consultant: Travere Therapeutics, Calliditas Therapeutics Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

This Fresh Take interview featured Ruth Williams-Brinkley, Regional President of Kaiser Permanente (Mid-Atlantic states). Ruth joined Francesca Ioffreda (VP, Inclusive Growth & Talent Initiatives) to discuss supporting inclusive growth initiatives, Kaiser's role in the community, and the importance of mental health.Hosted by Francesca Ioffreda.  Produced by Jenna Klym, Ramir Cena, , Nina Sharma, and Christian Rodriguez. Edited by Christian Rodriguez. and Ramir Cena Learn from leaders doing the work across the Capital Region and beyond. These conversations will showcase innovation, as well as history and culture across our region, to bridge the gap between how we got here and where we are going.About our guest:Ruth Williams-Brinkley is president of Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc. In this role, Williams-Brinkley oversees all of Kaiser Permanente's care delivery and health plan operations in Washington, D.C., and suburban Maryland, Baltimore, and Northern Virginia. The Mid-Atlantic States Region operates 36 medical office buildings and has 825,288 members.Williams-Brinkley has more than 40 years of executive experience in health care. She joined Kaiser Permanente in November 2017, serving as president of Kaiser Foundation Health Plan and Hospitals of the Northwest. She oversaw all of Kaiser Permanente's care delivery and health plan operations in Oregon and markets in Vancouver and Longview/Kelso, Washington.Prior to that, she served as CEO of KentuckyOne Health, Kentucky's largest integrated health system. KentuckyOne was a division of CommonSpirit Health, one of the nation's largest nonprofit health systems.Before joining KentuckyOne, Williams-Brinkley served as president and CEO of Carondelet Health Network in Tucson, Arizona, and as president and CEO of Memorial Healthcare System in Chattanooga, Tennessee.Williams-Brinkley serves on the boards of Travere Therapeutics, DePaul University, University of Phoenix, and the Clinical Center Research Hospital Board of the National Institutes of Health. She has been recognized by Modern Healthcare as one of the 100 Most Influential Leaders in Healthcare, one of the Top 25 Women in Healthcare, and one of the Top 25 Minority Executives in Healthcare, as well as one of Becker's most admired CEOs in health care.She holds a bachelor's degree and Master of Science degree from De Paul University, and an honorary doctoral degree from Spaulding University in Louisville, Kentucky.

While focal segmental glomerulosclerosis (FSGS) is rare overall, it is one of the most common glomerular diseases on Europe, North America and Latin America. Rather than being a specific disease entity, it is a pattern of injury that takes various forms that, together with the clinical presentation, have important implications for treatment and prognosis. Join Dr Sanjeev Sethi, pathologist at the Mayo Clinic, Rochester, Minnesota, USA, for an overview of our current understanding of how FSGS develops and presents. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. McGrogan A, Franssen CF, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414–430, 2011 2. Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH, Jacobsen SJ. Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. Am J Kidney Dis. 2016 Oct;68(4):533-544. 3. Rosenberg AZ, Koop JB. Focal segmental glomerulosclerosis. Clin J Am SOc Nephrol. 2017;12(3): 502-517. 4. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. 5. Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza F. Clinical and pathological phenotype of genetic casues of focal segmental glomerulosclerosis in adults. Clinical Kidney J. 2018;11 (2): 179-190. Disclosures: Dr Sanjeev Sethi has no relevant disclosures to report at this time. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and the most common glomerular disease worldwide. But its pathogenesis has not yet been fully elucidated, leaving some questions so far unanswered. Join Dr Richard Lafayette for an overview of our current understanding of how this disease develops and presents. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018 Apr 12;11:137-148. 2. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686. doi: 10.2215/CJN.07420716 3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. 4. Chang S, Li X-K. The role of immune modulation in pathogenesis of IGA nephropathy. Front Med.7:92. Disclosures: Dr Richard Lafayette declares the following: Research: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra Consulting: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.

The growing concerns about equity, diversity, and inclusion has had particular resonance in the area of rare disease, where health disparities have been felt throughout the community. Eve Dryer, vice president of patient advocacy for Travere Therapeutics, has been involved in a number of efforts to address these issues and her company has played a critical role in funding initiatives to address health disparities that result from racial and socioeconomic drivers. On the heels of the recently completed Global Genes 2021 RARE Health Equity Summit, we spoke to Dryer about why Travere has focused on these issues, the work it is doing, and why it is such a critical issue for the rare disease community.

Dr. Tushar Vachharajani has spent the last decade dedicating his time and effort to ISN Education and is one of the founders of The ISN Academy. The Academy has become one of the premier online educational resources in the field of hepatology and Dr. Vachharajani is stepping down as the Chair of Education Working Group that oversees the Academy. In his conversation with Roberto and Smeeta in this episode he provides the history of ISN's online education that culminated in the presentation of WCN'21, a full virtual congress. 

Smeeta Sinha was joined by guest host Sibel Bek, Assistant Professor, Kocaeli Univeristy Hosptial Kocaeli Turkey she is also an ISNEducation Social Media Team Deputy Chair. They are hosting a conversation with Kate Bramham, Consultant Nephrologist and Senior Clinical lecturer, King's College Hospital and Rolando Claure-Del Granado, Nephrology Chief of Service. Hospital Oberro No2-CNS, Cochabamba, BoliviaKate and Rolando are discussing their talks at the WCN'21 on the topic of AKI. 

Roberto and Smeeta are joined in conversation with Jeremy Hughes, Professor of Experimental Nephrology Honorary Consultant Nephrologist Royal Infirmary, Edinburgh and Dwomoa Adu, Honorary Consultant Nephrologist, Korle Bu Teaching Hospital. Senior Research Fellow, University of Ghana Medical School and Laura Sola, Nephrologist, Director of Hemodialysis Center. They discuss their talks at the WCN'21 and the broader topic of capacity building. 

Guest host Dr. Arvind Conjeevaram Consultant Nephrologist and Transplant Physician, Bangalore and @ISNeducation Social Media Team Chair sits down with Sofia Ahmed, Professor, Cumming School of Medicine, University of Calgary and Advisory Board Member, Canadian Institutes of Health Research Institute of Gender and Health  and Angela Webster, Transplant Physician, Westmead Hospital, Professor of Clinical Epidemiology, School of Public Health, University of Sydney. Director of Evidence Integration at the NHMRC Clinical Trials Center University of Sydney.   They discuss their upcoming talks at the WCN'21 and go deeper into the topic of Gender. 

One of our guest we bring you in this episode is a self-described industry dinosaur. The reason he can make a claim like that, of course, is his longevity. But also, perhaps without knowing it, he can make that claim because of the long-term impact he has had on health care. In fact, if you look back over the past 30 years of pharmaceuticals, you can see his fingerprints on so many of the advancements that we take for granted today. This dinosaur is Steve Aselage. He is a member of the board of directors of Travere Therapeutics where he previously was CEO. He is joined on this episode by his daughter, Beth Aselage, Associate Director of Advocacy Relations for Gossamer Bio. Beth speaks with a wisdom that combines analytical insights with an abiding desire to advocate on behalf of patients. She has a unique ability to harvest what is most important to patients and to fuse them into an ongoing development for pharmaceutical companies. Of course the insight that they offer is second-to-none. However, we wanted to bring you the two of them together for an even bigger reason. We wanted you to know about the depth of the legacy that a passion for serving patients can have. When that passion is more than just a saying, patient-first mentalities have the power to change our industry for years to come. Please subscribe and keep listening to Rare Voices! Music Credits: Westpoint Instrumental by  Sun Shapes

The rare disease drug developer Retrophin has been through a number of changes in recent years including a new CEO, a late-stage failure of a key program, and the resolution of dueling lawsuits between it and its former CEO and convicted fraudster Martin Shkreli. Now with data from its lead experimental therapy sparsentan expected next year in two different rare kidney diseases, the company has changed its name to Travere Therapeutics. We spoke to Eric Dube, CEO of Travere, about the company's new identity, its experimental therapy sparsentan, and the rare kidney diseases it is being developed to treat.